Glabellar Lines Clinical Trials

63 clinical trials for Glabellar Lines across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A PHASE III, MULTICENTRE, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE DOSE OF IPN10200 IN THE IMPROVEMENT OF MODERATE TO SEVERE GLABELLAR LINES IN ADULT PARTICIPANTS — RECRUITING · PHASE3
• To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III) — RECRUITING · PHASE3
• A DOUBLE-BLINDED RANDOMIZED CONTROLLED STUDY TO COMPARE THE EFFICACY, TIME TO ONSET, AND DURATION OF EFFECT OF BOTULINUM TYPE A TOXINS IN THE TREATMENT OF GLABELLAR FROWN LINES. — RECRUITING
• AN OPEN-LABEL, MULTI-CENTER TRIAL TO ASSESS THE SAFETY OF SINGLE AND REPEAT DAXIBOTULINUMTOXINA FOR INJECTION FOR TREATMENT OF MODERATE TO SEVERE GLABELLAR LINES (SAKURA OPEN-LABEL SAFETY) — RECRUITING
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DAXIBOTULINUMTOXINA FOR INJECTION TO TREAT MODERATE TO SEVERE GLABELLAR LINES (SAKURA 2) — RECRUITING · PHASE3
• A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOSE RANGING, ACTIVE AND PLACEBO CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY AND DURATION OF EFFECT OF RT002, A BOTULINUM TOXIN TYPE A FOR INJECTION, TO TREAT GLABELLAR LINES — RECRUITING · PHASE2
• EVALUATION OF THE SAFETY AND EFFICACY OF TREATMENT WITH BOTOX (BOTULIUNUM TOXIN TYPE A) PURIFIED NEUROTOXIN COMPLEX FOR SUBJECTS WITH FOREHEAD AND GLABELLAR FACIAL RHYTIDES — RECRUITING
• A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines — NOT_YET_RECRUITING · PHASE1
• A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines — COMPLETED · PHASE1
• A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines — COMPLETED · PHASE3
• Evaluate the Efficacy and Safety of INI101 Compared to BOTOX® in Subjects With Moderate to Severe Glabellar Lines. — COMPLETED · PHASE3
• Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure — COMPLETED
• A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines — COMPLETED · PHASE3
• A Prospective, Non-Interventional, Single-Centre Study Assessing the Efficacy of a Holistic Upper Face Treatment With Botulinum Neurotoxin A — COMPLETED
• A Study to Evaluate AI-09 In Participants With Glabellar Lines — ACTIVE_NOT_RECRUITING · PHASE2
• Integrated exploratory phase 1/2a study, double-blind, randomized, controlled to evaluate the Safety and Efficacy of FTP-002 / FTP-501 combination in the treatment of glabellar lines — OTHER · PHASE2
• A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) — COMPLETED · PHASE1
• A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines — COMPLETED · PHASE2
• Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines — COMPLETED · PHASE2
• Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin — COMPLETED
• A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines — COMPLETED · PHASE2
• Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines — NOT_YET_RECRUITING · PHASE3
• A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines — COMPLETED · PHASE3
• MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) — COMPLETED · PHASE3
• A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines — COMPLETED · PHASE3
• A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines — COMPLETED · PHASE3
• Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines — COMPLETED · PHASE1
• Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines — OTHER · PHASE3
• Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial — COMPLETED · PHASE3
• AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines — COMPLETED · PHASE2
• MT10109L in the Treatment of Glabellar Lines — COMPLETED · PHASE3
• MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines — COMPLETED · PHASE3
• Phase 2 of HU-045 in Glabellar Lines — COMPLETED · PHASE2
• Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines — COMPLETED · PHASE3
• MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL) — COMPLETED · PHASE3
• Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines — COMPLETED · PHASE1
• Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines — COMPLETED · PHASE1
• Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines — COMPLETED · PHASE3
• Treatment of Moderate to Severe Glabellar Lines (BMI2006) — COMPLETED · PHASE3
• Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines — COMPLETED · PHASE4
• Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines. — COMPLETED · PHASE3
• To Compare the Safety and Efficacy of "HG-102" With Botox® in the Improvement of Moderate to Severe Glabellar Lines. — COMPLETED · PHASE1
• A PHASE 3, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AGN-151586 FOR THE TREATMENT OF GLABELLAR LINES — COMPLETED · PHASE3
• Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines — COMPLETED · PHASE3
• Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport® — COMPLETED
• A PHASE 2, MULTICENTER, OPEN LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAXIBOTULINUMTOXINA FOR INJECTION (DAXI FOR INJECTION) FOR THE COMBINED TREATMENT OF UPPER FACIAL LINES (GLABELLAR LINES, DYNAMIC FOREHEAD LINES AND LATERAL CANTHAL LINES) — NOT_YET_RECRUITING · PHASE2
• "A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QM1114-DP FOR THE TREATMENT OF MODERATE TO SEVERE GLABELLAR LINES (READY - 1)." — COMPLETED
• "A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QM1114-DP FOR THE TREATMENT OF MODERATE TO SEVERE LATERAL CANTHAL LINES AND GLABELLAR LINES ALONE OR IN COMBINATION (READY-3)." — COMPLETED
• Dysport in the Treatment of Glabellar Lines in Chinese Subjects — COMPLETED · PHASE3
• Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines — COMPLETED · PHASE3

Refine this search